Apellis Pharmaceuticals Inc (FRA:1JK)
€ 36.59 -0.37 (-1%) Market Cap: 4.53 Bil Enterprise Value: 4.33 Bil PE Ratio: 0 PB Ratio: 18.22 GF Score: 49/100

Apellis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 04:20PM GMT
Release Date Price: €85.5 (+2.40%)
Unidentified Analyst

Thanks, everyone, for joining us Day 3 of the Goldman Sachs Global Healthcare Conference. And obviously, we're thrilled to be joined by the team from Apellis Pharmaceuticals. I mean, not a lot going on, so it's kind of show time for you all. I think I'll start with the first question, what's with the hat?

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Yes, I'm a big Boston Red Sox fan now...

Unidentified Company Representative

Boston Soccer fan. That's awesome. Thank you.

Questions & Answers

Unidentified Analyst

Amazing. Excellent. All right. So let's start at a very high level, then we'll kind of dive right into it. Walk us through how the launch of SYFOVRE, you're recently approved drug in geographic atrophy is progressing?

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you so much, [Medwin], and thank you, everyone, for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot